<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407625</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092016-026</org_study_id>
    <nct_id>NCT03407625</nct_id>
  </id_info>
  <brief_title>Foley Bulb With Oral Misoprostol for Induction of Labor</brief_title>
  <official_title>Foley Bulb With Oral Misoprostol Versus Oral Misoprostol for Induction of Labor: A Cluster Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of labor is associated with increased cesarean delivery rates, particularly in&#xD;
      women with an unfavorable cervix. Both pharmacologic and mechanical methods are utilized for&#xD;
      cervical ripening and labor induction. Evidence on the safety and effectiveness of various&#xD;
      mechanical and pharmacologic methods of cervical ripening and labor induction is abundant,&#xD;
      and yet the majority of clinical trials evaluate time to delivery, rather than mode of&#xD;
      delivery. This is a prospective, cluster-randomized clinical trial to compare a standard&#xD;
      method of induction at our institution (oral misoprostol) with an alternative, commonly used&#xD;
      combination method of oral misoprostol and transcervical foley bulb in women with term&#xD;
      pregnancies requiring induction of labor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the use of a transcervical foley catheter,&#xD;
      in combination with the standard oral misoprostol regimen will result in a decreased primary&#xD;
      cesarean delivery rate among women with a cervical dilation of 2 centimeters of less who&#xD;
      require induction of labor at term. This study is not an FDA-regulated study: there is no&#xD;
      intent to test the foley bulb under an FDA-regulated protocol. Likewise, there is no intent&#xD;
      to submit the results of this study for a change in the labeling of the foley used for this&#xD;
      study. This study was approved by the Institutional Review Board of the University of Texas&#xD;
      Southwestern Medical Center, and by the Office of Research Administration at Parkland Health&#xD;
      and Hospital System.&#xD;
&#xD;
      This will be a prospective, cluster-randomized trial comparing two accepted methods of&#xD;
      induction of labor at term among women who present for delivery at Parkland Hospital.&#xD;
      Eligible participants will include nulliparous and multiparous women at 37 weeks gestation or&#xD;
      greater, with a living, singleton fetus and no major fetal malformations, in cephalic&#xD;
      presentation, with intact membranes, no prior uterine scar, who qualify for prostaglandin&#xD;
      administration and who have a cervical dilation of 2 centimeters or less, measured at the&#xD;
      level of the internal os. Patients with latex allergy, non-reassuring fetal status, HIV,&#xD;
      active herpes outbreak, a prior uterine scar, or any contraindication to prostaglandins&#xD;
      (including 4 or more painful contractions per 10 minutes prior to prostaglandin&#xD;
      administration) will be excluded from participation in the study.&#xD;
&#xD;
      Computer-generated cluster randomization will occur on a weekly basis for all study&#xD;
      participants, to either the combination method of foley bulb plus oral misoprostol regimen&#xD;
      (study group) or to oral misoprostol alone regimen (control).&#xD;
&#xD;
      According to the randomization protocol each week, participants will be randomized to either&#xD;
      the standard of care (oral misoprostol/control group) or standard of care plus foley bulb&#xD;
      (study group). The study group will undergo placement of a 30 French foley catheter filled&#xD;
      with 30-35cc sterile saline into the cervix in addition to the standard regimen of oral&#xD;
      misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses, for patients who&#xD;
      meet criteria for fetal well-being, and do not had more than 4 painful contractions in 10&#xD;
      minutes. Misoprostol will not be administered to patients who have progressed to active&#xD;
      labor, defined as 4 centimeters cervical dilation. The control group will undergo induction&#xD;
      with our current standard oral misoprostol protocol alone, administered as 100 micrograms&#xD;
      given every 4 hours for a maximum of 2 doses. Both groups will receive oxytocin as indicated&#xD;
      by current labor protocols at our institution.&#xD;
&#xD;
      The primary outcome will be the rate of vaginal delivery. Secondary outcomes will include&#xD;
      obstetric outcomes, maternal outcomes, and neonatal outcomes. Obstetric outcomes will include&#xD;
      indication for induction, need for oxytocin, indication for cesarean delivery, time to active&#xD;
      labor, time to delivery, labor analgesia, presence of chorioamnionitis, meconium-stained&#xD;
      amniotic fluid, terbutaline use, tachysystole (defined as 6 or more contractions in 10&#xD;
      minutes or tetanic contraction of 120 seconds or longer) or hyperstimulation syndrome&#xD;
      (defined as tachysystole accompanied by fetal heart rate decelerations). Maternal outcomes&#xD;
      will include estimated blood loss, transfusion requirement, postpartum fever, uterine&#xD;
      rupture, and unplanned hysterectomy. Neonatal outcomes will include umbilical cord blood pH,&#xD;
      5-minute APGAR score, intubation or ventilation in the delivery room, neonatal sepsis, and&#xD;
      admission to Neonatal Intensive Care Unit (NICU) admission.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">May 13, 2019</completion_date>
  <primary_completion_date type="Actual">May 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cluster randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vaginal Delivery</measure>
    <time_frame>at delivery</time_frame>
    <description>vaginal delivery at first induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Delivery</measure>
    <time_frame>from start of induction agent to time of delivery</time_frame>
    <description>Time (in hours) from start of induction agent to delivery at first induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for Cesarean Delivery</measure>
    <time_frame>at delivery</time_frame>
    <description>Among women delivered by cesarean, the indication for cesarean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of Oxytocin Given (mcg or mg)</measure>
    <time_frame>at delivery</time_frame>
    <description>Total dose of oxytocin given for induction as calculated by volume infused, concentration of solution and rate of infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time With Foley Bulb in Place</measure>
    <time_frame>From time of documented insertion until the time of documented expulsion or removal, whichever came first, assessed up to 24 hours.</time_frame>
    <description>time (in hours) from insertion to removal or expulsion of foley bulb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Chorioamnionitis</measure>
    <time_frame>at delivery</time_frame>
    <description>Intrapartum fever (temp equal or greater than 38C) with no other identified cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Intravenous Analgesia During Labor</measure>
    <time_frame>at delivery</time_frame>
    <description>Intravenous analgesia used between the start of induction and delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Used Neuraxial Analgesia During Labor</measure>
    <time_frame>from start of induction to delivery</time_frame>
    <description>Regional or neuraxial analgesia (labor epidural or spinal) used between the start of induction and delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Used General Anesthesia for Delivery</measure>
    <time_frame>at delivery</time_frame>
    <description>General anesthesia administered for delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Meconium-stained Amniotic Fluid</measure>
    <time_frame>At the time of rupture of membranes and at delivery</time_frame>
    <description>Identification of any meconium (green tinge) in the amniotic fluid before or during delivery by a healthcare provider's assessment of gross fluid color.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terbutaline Use</measure>
    <time_frame>at delivery</time_frame>
    <description>Administration of terbutaline, a tocolytic agent, for tetanic contractions with or without fetal heart rate decelerations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tachysystole</measure>
    <time_frame>at delivery</time_frame>
    <description>6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Uterine Hyperstimulation Syndrome</measure>
    <time_frame>at delivery</time_frame>
    <description>Tachysystole accompanied by fetal heart rate decelerations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Excess Blood Loss</measure>
    <time_frame>at delivery</time_frame>
    <description>Maternal excess blood loss is defined as &gt;500ml for vaginal and &gt;1000ml for cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Transfusion</measure>
    <time_frame>at delivery</time_frame>
    <description>administration of blood products related to delivery blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Uterine Rupture</measure>
    <time_frame>at delivery</time_frame>
    <description>spontaneous separation of myometrium in a previously intact, unscarred uterus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unplanned Hysterectomy</measure>
    <time_frame>at discharge from the hospital following delivery</time_frame>
    <description>unplanned removal of the uterus following delivery of the fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postpartum Fever</measure>
    <time_frame>Following delivery and prior to discharge</time_frame>
    <description>Fever recorded in the time after delivery but prior to discharge from the hospital, with clinical assessment of endometritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Umbilical Cord Blood pH &lt;7.0</measure>
    <time_frame>at delivery</time_frame>
    <description>Arterial or venous cord blood pH defined as &lt;7.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an 5-minute Apgar Score Less Than 4</measure>
    <time_frame>5 minutes after time of birth</time_frame>
    <description>Appearance, Pulse, Grimace, Activity, Respirations - scored from 0 to 2 for each component, added to make a total score and used as an assessment of initial response to newborn resuscitation, lower scores associated with poor outcomes. Here defined as Apgar less than 4 at 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No)</measure>
    <time_frame>at delivery</time_frame>
    <description>Intubation with mechanical support or control of neonatal breathing in delivery room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Administered Neonatal Antibiotics and/or Neonatal Blood Cultures</measure>
    <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
    <description>Administration of neonatal antibiotics and/or neonatal blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neonatal Sepsis</measure>
    <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
    <description>Neonatal bacteremia as defined by bacterial growth in blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With NICU Admission Order</measure>
    <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
    <description>Admission order to neonatal intensive care unit (NICU) placed between the time of delivery and infant discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2227</enrollment>
  <condition>Pregnancy</condition>
  <condition>Labor, Induced</condition>
  <arm_group>
    <arm_group_label>Foley bulb plus Oral Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Foley bulb plus Oral Misoprostol</intervention_name>
    <description>Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
    <arm_group_label>Foley bulb plus Oral Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Misoprostol</intervention_name>
    <description>Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
    <arm_group_label>Oral Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  37 weeks gestation or greater&#xD;
&#xD;
          -  Living, singleton fetus&#xD;
&#xD;
          -  No major fetal malformations&#xD;
&#xD;
          -  Cephalic presentation&#xD;
&#xD;
          -  No prior uterine scar&#xD;
&#xD;
          -  Intact fetal membranes&#xD;
&#xD;
          -  Qualifies for prostaglandin administration according to current Parkland protocol&#xD;
&#xD;
          -  Have a cervical dilation of 2 centimeters or less, measured at the level of the&#xD;
             internal os&#xD;
&#xD;
          -  Have an indication for induction or attempted induction of labor according to Parkland&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  latex allergy&#xD;
&#xD;
          -  non-reassuring fetal status&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  active herpes outbreak&#xD;
&#xD;
          -  Prior uterine scar&#xD;
&#xD;
          -  Contraindication to prostaglandins according to current Parkland protocol&#xD;
&#xD;
          -  Contraindication to vaginal delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily H Adhikari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Health and Hospital Systems</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <results_first_submitted>September 11, 2020</results_first_submitted>
  <results_first_submitted_qc>October 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Emily Adhikari</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Labor Induction</keyword>
  <keyword>Cervical Ripening</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03407625/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Foley Bulb Plus Oral Misoprostol</title>
          <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
        </group>
        <group group_id="P2">
          <title>Oral Misoprostol</title>
          <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1117"/>
                <participants group_id="P2" count="1110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1117"/>
                <participants group_id="P2" count="1110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Foley Bulb Plus Oral Misoprostol</title>
          <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
        </group>
        <group group_id="B2">
          <title>Oral Misoprostol</title>
          <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1117"/>
            <count group_id="B2" value="1110"/>
            <count group_id="B3" value="2227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="6.6"/>
                    <measurement group_id="B2" value="26.6" spread="6.7"/>
                    <measurement group_id="B3" value="26.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1117"/>
                    <measurement group_id="B2" value="1110"/>
                    <measurement group_id="B3" value="2227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="840"/>
                    <measurement group_id="B2" value="860"/>
                    <measurement group_id="B3" value="1700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1117"/>
                    <measurement group_id="B2" value="1110"/>
                    <measurement group_id="B3" value="2227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Parity = 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="591"/>
                    <measurement group_id="B2" value="584"/>
                    <measurement group_id="B3" value="1175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="313"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Parity = &gt; 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="6.7"/>
                    <measurement group_id="B2" value="30.1" spread="7.2"/>
                    <measurement group_id="B3" value="29.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="977"/>
                    <measurement group_id="B2" value="952"/>
                    <measurement group_id="B3" value="1929"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gestational</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pregestational</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at delivery (weeks)</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="38" upper_limit="40"/>
                    <measurement group_id="B2" value="39" lower_limit="38" upper_limit="40"/>
                    <measurement group_id="B3" value="39" lower_limit="38" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaginal Delivery</title>
        <description>vaginal delivery at first induction</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaginal Delivery</title>
          <description>vaginal delivery at first induction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1,117"/>
                <count group_id="O2" value="1,110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869"/>
                    <measurement group_id="O2" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>log binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <other_analysis_desc>We used generalized estimating equations for the log binomial regression with cluster entered as a random effect.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Delivery</title>
        <description>Time (in hours) from start of induction agent to delivery at first induction</description>
        <time_frame>from start of induction agent to time of delivery</time_frame>
        <population>This number represents women delivered at first induction</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Delivery</title>
          <description>Time (in hours) from start of induction agent to delivery at first induction</description>
          <population>This number represents women delivered at first induction</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1088"/>
                <count group_id="O2" value="1075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="9.2"/>
                    <measurement group_id="O2" value="18.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Indication for Cesarean Delivery</title>
        <description>Among women delivered by cesarean, the indication for cesarean</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Indication for Cesarean Delivery</title>
          <description>Among women delivered by cesarean, the indication for cesarean</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Labor dystocia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal fetal heart rate tracing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Malpresentation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No cesarean delivery</title>
                  <measurement_list>
                    <measurement group_id="O1" value="882"/>
                    <measurement group_id="O2" value="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose of Oxytocin Given (mcg or mg)</title>
        <description>Total dose of oxytocin given for induction as calculated by volume infused, concentration of solution and rate of infusion</description>
        <time_frame>at delivery</time_frame>
        <population>Total dose of oxytocin was not found to be meaningful, thus data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Oxytocin Given (mcg or mg)</title>
          <description>Total dose of oxytocin given for induction as calculated by volume infused, concentration of solution and rate of infusion</description>
          <population>Total dose of oxytocin was not found to be meaningful, thus data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time With Foley Bulb in Place</title>
        <description>time (in hours) from insertion to removal or expulsion of foley bulb</description>
        <time_frame>From time of documented insertion until the time of documented expulsion or removal, whichever came first, assessed up to 24 hours.</time_frame>
        <population>Number of women with successful Foley bulb placement</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time With Foley Bulb in Place</title>
          <description>time (in hours) from insertion to removal or expulsion of foley bulb</description>
          <population>Number of women with successful Foley bulb placement</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="945"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.6" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Chorioamnionitis</title>
        <description>Intrapartum fever (temp equal or greater than 38C) with no other identified cause</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Chorioamnionitis</title>
          <description>Intrapartum fever (temp equal or greater than 38C) with no other identified cause</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Intravenous Analgesia During Labor</title>
        <description>Intravenous analgesia used between the start of induction and delivery</description>
        <time_frame>at delivery</time_frame>
        <population>Intravenous analgesia was not clinically meaningful and was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Intravenous Analgesia During Labor</title>
          <description>Intravenous analgesia used between the start of induction and delivery</description>
          <population>Intravenous analgesia was not clinically meaningful and was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Used Neuraxial Analgesia During Labor</title>
        <description>Regional or neuraxial analgesia (labor epidural or spinal) used between the start of induction and delivery</description>
        <time_frame>from start of induction to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Used Neuraxial Analgesia During Labor</title>
          <description>Regional or neuraxial analgesia (labor epidural or spinal) used between the start of induction and delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949"/>
                    <measurement group_id="O2" value="935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Used General Anesthesia for Delivery</title>
        <description>General anesthesia administered for delivery</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Used General Anesthesia for Delivery</title>
          <description>General anesthesia administered for delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Meconium-stained Amniotic Fluid</title>
        <description>Identification of any meconium (green tinge) in the amniotic fluid before or during delivery by a healthcare provider's assessment of gross fluid color.</description>
        <time_frame>At the time of rupture of membranes and at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Meconium-stained Amniotic Fluid</title>
          <description>Identification of any meconium (green tinge) in the amniotic fluid before or during delivery by a healthcare provider's assessment of gross fluid color.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terbutaline Use</title>
        <description>Administration of terbutaline, a tocolytic agent, for tetanic contractions with or without fetal heart rate decelerations</description>
        <time_frame>at delivery</time_frame>
        <population>Terbutaline use was not felt to be clinically meaningful, and thus data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Terbutaline Use</title>
          <description>Administration of terbutaline, a tocolytic agent, for tetanic contractions with or without fetal heart rate decelerations</description>
          <population>Terbutaline use was not felt to be clinically meaningful, and thus data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tachysystole</title>
        <description>6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tachysystole</title>
          <description>6 or more contractions in 10 minutes or tetanic contraction of 120 seconds or longer</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Uterine Hyperstimulation Syndrome</title>
        <description>Tachysystole accompanied by fetal heart rate decelerations</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Uterine Hyperstimulation Syndrome</title>
          <description>Tachysystole accompanied by fetal heart rate decelerations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Excess Blood Loss</title>
        <description>Maternal excess blood loss is defined as &gt;500ml for vaginal and &gt;1000ml for cesarean delivery</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Excess Blood Loss</title>
          <description>Maternal excess blood loss is defined as &gt;500ml for vaginal and &gt;1000ml for cesarean delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Transfusion</title>
        <description>administration of blood products related to delivery blood loss</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Transfusion</title>
          <description>administration of blood products related to delivery blood loss</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Uterine Rupture</title>
        <description>spontaneous separation of myometrium in a previously intact, unscarred uterus</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Uterine Rupture</title>
          <description>spontaneous separation of myometrium in a previously intact, unscarred uterus</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unplanned Hysterectomy</title>
        <description>unplanned removal of the uterus following delivery of the fetus</description>
        <time_frame>at discharge from the hospital following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unplanned Hysterectomy</title>
          <description>unplanned removal of the uterus following delivery of the fetus</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postpartum Fever</title>
        <description>Fever recorded in the time after delivery but prior to discharge from the hospital, with clinical assessment of endometritis</description>
        <time_frame>Following delivery and prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postpartum Fever</title>
          <description>Fever recorded in the time after delivery but prior to discharge from the hospital, with clinical assessment of endometritis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Umbilical Cord Blood pH &lt;7.0</title>
        <description>Arterial or venous cord blood pH defined as &lt;7.0</description>
        <time_frame>at delivery</time_frame>
        <population>This number represents available umbilical cord blood gas</population>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Umbilical Cord Blood pH &lt;7.0</title>
          <description>Arterial or venous cord blood pH defined as &lt;7.0</description>
          <population>This number represents available umbilical cord blood gas</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1085"/>
                <count group_id="O2" value="1088"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an 5-minute Apgar Score Less Than 4</title>
        <description>Appearance, Pulse, Grimace, Activity, Respirations - scored from 0 to 2 for each component, added to make a total score and used as an assessment of initial response to newborn resuscitation, lower scores associated with poor outcomes. Here defined as Apgar less than 4 at 5 minutes.</description>
        <time_frame>5 minutes after time of birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an 5-minute Apgar Score Less Than 4</title>
          <description>Appearance, Pulse, Grimace, Activity, Respirations - scored from 0 to 2 for each component, added to make a total score and used as an assessment of initial response to newborn resuscitation, lower scores associated with poor outcomes. Here defined as Apgar less than 4 at 5 minutes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No)</title>
        <description>Intubation with mechanical support or control of neonatal breathing in delivery room</description>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No)</title>
          <description>Intubation with mechanical support or control of neonatal breathing in delivery room</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Administered Neonatal Antibiotics and/or Neonatal Blood Cultures</title>
        <description>Administration of neonatal antibiotics and/or neonatal blood cultures</description>
        <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Administered Neonatal Antibiotics and/or Neonatal Blood Cultures</title>
          <description>Administration of neonatal antibiotics and/or neonatal blood cultures</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neonatal Sepsis</title>
        <description>Neonatal bacteremia as defined by bacterial growth in blood cultures</description>
        <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neonatal Sepsis</title>
          <description>Neonatal bacteremia as defined by bacterial growth in blood cultures</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With NICU Admission Order</title>
        <description>Admission order to neonatal intensive care unit (NICU) placed between the time of delivery and infant discharge</description>
        <time_frame>From time of birth until the time of discharge or up to 7 days of life, whichever comes first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Foley Bulb Plus Oral Misoprostol</title>
            <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
          </group>
          <group group_id="O2">
            <title>Oral Misoprostol</title>
            <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With NICU Admission Order</title>
          <description>Admission order to neonatal intensive care unit (NICU) placed between the time of delivery and infant discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From delivery to hospital discharge</time_frame>
      <desc>The risk of transcervical foley bulb is minimal, and the primary risk of participation in the study is breach of confidentiality. Risk associated with Foley bulb is not increased above the risks associated with vaginal or cesarean delivery; adverse maternal and neonatal outcomes are reported as secondary outcomes in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Foley Bulb Plus Oral Misoprostol</title>
          <description>Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Foley bulb plus Oral Misoprostol: Although labeled &quot;experimental&quot; for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.</description>
        </group>
        <group group_id="E2">
          <title>Oral Misoprostol</title>
          <description>Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.&#xD;
Oral Misoprostol: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1110"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pre-specified outcomes (dose of Oxytocin give at the delivery, terbutaline use, and the number of participants with intravenous analgesia during labor) were not collected as they were found to be not meaningful.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emily Adhikari, MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-7825</phone>
      <email>emily.adhikari@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

